Insider Selling: Masimo Corp. (MASI) CEO Sells 400 Shares of Stock
Masimo Corp. (NASDAQ:MASI) CEO Joe E. Kiani sold 400 shares of the business’s stock in a transaction on Tuesday, September 20th. The stock was sold at an average price of $60.16, for a total value of $24,064.00. Following the sale, the chief executive officer now owns 120,240 shares in the company, valued at approximately $7,233,638.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Shares of Masimo Corp. (NASDAQ:MASI) traded up 0.91% on Wednesday, reaching $59.85. The company’s stock had a trading volume of 168,602 shares. Masimo Corp. has a 12 month low of $33.03 and a 12 month high of $60.46. The stock has a 50 day moving average of $58.32 and a 200-day moving average of $49.77. The firm has a market cap of $2.95 billion, a price-to-earnings ratio of 31.38 and a beta of 0.80.
Masimo Corp. (NASDAQ:MASI) last posted its earnings results on Wednesday, August 3rd. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.16. The firm had revenue of $172.64 million for the quarter, compared to the consensus estimate of $166.02 million. Masimo Corp. had a return on equity of 29.07% and a net margin of 15.40%. The business’s quarterly revenue was up 10.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.36 earnings per share. On average, analysts anticipate that Masimo Corp. will post $2.02 EPS for the current year.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/insider-selling-masimo-corp-masi-ceo-sells-400-shares-of-stock.html
Large investors have recently bought and sold shares of the company. Norges Bank bought a new stake in Masimo Corp. during the fourth quarter valued at about $20,667,000. Aperio Group LLC increased its stake in shares of Masimo Corp. by 27.3% in the first quarter. Aperio Group LLC now owns 15,761 shares of the company’s stock worth $659,000 after buying an additional 3,379 shares during the period. Virginia Retirement System acquired a new stake in shares of Masimo Corp. during the first quarter worth about $1,452,000. Pacad Investment Ltd. acquired a new stake in shares of Masimo Corp. during the first quarter worth about $519,000. Finally, Los Angeles Capital Management & Equity Research Inc. increased its stake in shares of Masimo Corp. by 0.7% in the first quarter. Los Angeles Capital Management & Equity Research Inc. now owns 56,685 shares of the company’s stock worth $2,372,000 after buying an additional 400 shares during the period. Hedge funds and other institutional investors own 79.88% of the company’s stock.
A number of brokerages recently weighed in on MASI. BTIG Research restated a “hold” rating on shares of Masimo Corp. in a research report on Friday, August 5th. Piper Jaffray Cos. restated an “overweight” rating and set a $55.00 price objective (up previously from $52.00) on shares of Masimo Corp. in a research report on Friday, August 5th. Wedbush restated an “outperform” rating and set a $63.00 price objective (up previously from $60.00) on shares of Masimo Corp. in a research report on Thursday, August 4th. Finally, Raymond James Financial Inc. lowered Masimo Corp. from a “strong-buy” rating to an “outperform” rating in a research report on Wednesday, June 1st. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Masimo Corp. presently has an average rating of “Buy” and an average target price of $52.60.
Masimo Corp. Company Profile
Masimo Corporation is a medical technology company that develops, manufactures and markets non-invasive patient monitoring products. The Company’s business is measure-through-motion and low-perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry. Its product offerings include monitoring blood constituents with an optical signature, optical organ oximetry monitoring, electrical brain function monitoring, acoustic respiration monitoring and exhaled gas monitoring.
Receive News & Ratings for Masimo Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo Corp. and related companies with MarketBeat.com's FREE daily email newsletter.